HEALTH

FDA approves new version of diabetes drug Mounjaro for weight loss

Nov 8, 2023, 11:36 AM | Updated: 11:44 am

This image provided by Eli Lilly on Wednesday, Nov. 8, 2023 shows packaging for their new drug Zepb...

This image provided by Eli Lilly on Wednesday, Nov. 8, 2023 shows packaging for their new drug Zepbound. The new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, the U.S. Food and Drug Administration announced Wednesday. (Eli Lilly)

(Eli Lilly)

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday.

The U.S. Food and Drug Administration approved Eli Lilly’s Zepbound, or tirzepatide. The drug helped dieters lose about a quarter of their body weight, or 60 pounds (27 kilograms), in a recent study.

Zepbound is the latest diabetes drug approved for weight loss, joining Novo Nordisk’s Wegovy, a high-dose version of its diabetes treatment Ozempic.

The FDA approved Lilly’s drug for people who are considered obese, with a body mass index of 30 or higher, or those who are overweight with a related health condition, like high blood pressure, high cholesterol or diabetes. The drug should be paired with a healthy diet and regular exercise, the FDA said.

In the U.S., at least 100 million adults and about 15 million children are considered obese.

The drug tirzepatide in Zepbound and Mounjaro and semaglutide in Wegovy and Ozempic work by mimicking hormones that kick in after people eat to regulate appetite and the feeling of fullness. Both imitate a hormone called glucagon-like peptide-1, known as GLP-1. Tirzepatide targets a second hormone, called glucose-dependent insulinotropic polypeptide, or GIP.

Zepbound appears to spur greater weight loss than Wegovy. Approved for chronic weight management in 2021, Wegovy helped people lose about 15% of their body weight or 34 pounds (15.4 kilograms), according to study results.

“This would be the most highly efficacious drug ever approved for the treatment of obesity,” said Dr. Fatima Cody Stanford, an obesity medicine expert at Massachusetts General Hospital in Boston.

Touted by celebrities and on social media, semaglutide and tirzepatide drugs have already been in such demand that their manufacturers have struggled to keep up. Both have been listed on the FDA’s drug shortage site for months. All strengths of tirzepatide are currently listed as available, but a company spokesperson said that could vary by location and demand.

Side effects of the new weight-loss drug include vomiting, nausea, diarrhea, constipation and other gastrointestinal problems. In the most recent published trial, about 10% of people taking tirzepatide dropped out of the study because of such problems, compared to about 2% of people taking dummy shots.

While experts lauded approval of Zepbound, they worried that it wouldn’t necessarily mean greater access to the drug, which has been prescribed “off-label” to help people pare pounds.

“Most patients won’t be able to afford Zepbound without insurance coverage and many health plans exclude obesity care,” said Dr. Katherine Saunders, an obesity expert at New York’s Weill Cornell Medicine and co-founder of company focused on obesity treatment.

Eli Lilly and Co. said the list price for will be about $1,000 a month, the same as Mounjaro. Medicare is prohibited from covering drugs specifically for weight loss.

Kelly Burns, 50, of St. Petersburg, Florida, lost nearly 100 pounds (45 kilograms) using tirzepatide after joining a study of the drug to treat obesity in 2021. When testing ended and she no longer had access to the medication, she struggled, but eventually lost another 50 pounds (23 kilograms).

“My whole life is completely different,” she said. Her health measurements improved and her confidence soared. Now that is approved for weight loss, Burns plans to ask her insurance company about coverage. “It would be ridiculous not to,” she said, adding: “I want to stay this way as long as I possibly can.”

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

KSL 5 TV Live

Health

We're all guilty of slouching in our chairs. But did you know poor posture can cause serious health...

Emma Benson

Straightening up: How your posture affects your health

We're all guilty of slouching in our chairs. But did you know poor posture can cause serious health issues?

4 days ago

FILE: Marijuana plants are grown at Essence Vegas' 54,000-square-foot marijuana cultivation facilit...

Carla K. Johnson, AP Medical Writer

Daily marijuana use outpaces daily drinking in the US, a new study says

Millions of people in the U.S. report using marijuana daily or nearly every day, and those people now outnumber those who say they are daily or nearly-daily drinkers of alcohol.

4 days ago

A special humanitarian medical mission is underway in the Kingdom of Morocco involving 82 soldiers ...

Shara Park

Utah National Guard soldiers on humanitarian medical mission to Morocco

A special humanitarian medical mission is underway in the Kingdom of Morocco involving 82 soldiers from the Utah National Guard.

6 days ago

The first FDA-approved pill to treat postpartum depression was approved a few months ago, and it's ...

Jessica Guay, CNN

New hope for moms with postpartum depression

The first FDA-approved pill to treat postpartum depression was approved a few months ago, and it's already helping moms in the Pittsburgh area.

8 days ago

Diego Luna discusses his mental health struggles during his second season as a midfielder for Real ...

Emma Benson

‘It’s very difficult’: RSL’s Diego Luna opens up about mental health struggles

Luna, a California native and Olympic hopeful, is in his second season as a midfielder for Real Salt Lake. He admits the season was off to a rocky start. Pressures on and off the field, including becoming a father, were affecting his mental state.

8 days ago

TEMPE, ARIZONA - APRIL 17: Connor McDavid #97 of the Edmonton Oilers attempts a shot on goaltender ...

Stephen Whyno, AP Sports Writer

Connor Ingram wins the Masterton Trophy for perseverance and dedication to hockey

Connor Ingram, the goaltender for the Arizona Coyotes, has won the Bill Masterton Memorial Trophy after sharing his story with mental health struggles.

8 days ago

Sponsored Articles

Electrician repairing ceiling fan with lamps indoors...

Lighting Design

Stay cool this summer with ceiling fans

When used correctly, ceiling fans help circulate cool and warm air. They can also help you save on utilities.

Side view at diverse group of children sitting in row at school classroom and using laptops...

PC Laptops

5 Internet Safety Tips for Kids

Read these tips about internet safety for kids so that your children can use this tool for learning and discovery in positive ways.

Women hold card for scanning key card to access Photocopier Security system concept...

Les Olson

Why Printer Security Should Be Top of Mind for Your Business

Connected printers have vulnerable endpoints that are an easy target for cyber thieves. Protect your business with these tips.

Modern chandelier hanging from a white slanted ceiling with windows in the backgruond...

Lighting Design

Light Up Your Home With These Top Lighting Trends for 2024

Check out the latest lighting design trends for 2024 and tips on how you can incorporate them into your home.

Technician woman fixing hardware of desktop computer. Close up....

PC Laptops

Tips for Hassle-Free Computer Repairs

Experiencing a glitch in your computer can be frustrating, but with these tips you can have your computer repaired without the stress.

Close up of finger on keyboard button with number 11 logo...

PC Laptops

7 Reasons Why You Should Upgrade Your Laptop to Windows 11

Explore the benefits of upgrading to Windows 11 for a smoother, more secure, and feature-packed computing experience.

FDA approves new version of diabetes drug Mounjaro for weight loss